Exkivity (mobocertinib) / Takeda  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Exkivity (mobocertinib) / Takeda
EXCLAIM-2, NCT04129502 / 2019-001845-42: TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Active, not recruiting
3
354
Europe, Canada, Japan, US, RoW
TAK-788, AP32788, Mobocertinib, Pemetrexed, Alimta, Cisplatin, Carboplatin
Takeda
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
12/24
12/24

Download Options